Challenges in the development of heteromer-GPCR-based drugs

Progress in Molecular Biology and Translational Science

Volumn 117, Issue , 2013, Pages 143-162

  Franco, Rafael ^a,b   Martínez Pinilla, Eva ^a   Ricobaraza, Ana ^a   McCormick, Peter J ^b,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Cross talk; Drug discovery; Energy landscape; Fingerprint; Heptaspanning; Screening; Arrestin

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DRUG; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HETERODIMER; POSTSYNAPTIC RECEPTOR;

ALLOSTERISM; ANIMAL; ARTICLE; BINDING ASSAY; BINDING SITE; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; HUMAN; LIGAND BINDING; METABOLISM; MOLECULARLY TARGETED THERAPY; NONHUMAN; OLIGOMERIZATION; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION;

EID: 84896689116     PISSN: 18771173     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386931-9.00006-4     Document Type: Chapter

References (88)

1. A. Manglik, A.C. Kruse, T.S. Kobilka, F.S. Thian, J.M. Mathiesen, and R.K. Sunahara Crystal structure of the μ-opioid receptor bound to a morphinan antagonist Nature 485 2012 321 326
2. A. Claing, S.A. Laporte, M.G. Caron, and R.J. Lefkowitz Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins Prog Neurobiol 66 2002 61 79 [Review]
3. R. Franco, V. Casadó, F. Ciruela, J. Mallol, C. Lluis, and E.I. Canela The cluster-arranged cooperative model: a model that accounts for the kinetics of binding to A1 adenosine receptors Biochemistry 35 1996 3007 3015
4. R. Franco, M. Canals, D. Marcellino, S. Ferré, L. Agnati, and J. Mallol Regulation of heptaspanning-membrane-receptor function by dimerization and clustering Trends Biochem Sci 28 2003 238 243
5. M. Escriche, J. Burgueno, F. Ciruela, E.I. Canela, J. Mallol, and C. Enrich Ligand-induced caveolae-mediated internalization of A(1) adenosine receptors: morphological evidence of endosomal sorting and receptor recycling Exp Cell Res 285 2003 72 90
6. C.A. Saura, J. Mallol, E.I. Canela, C. Lluis, and R. Franco Adenosine deaminase and A1 adenosine receptors internalize together following agonist-induced receptor desensitization J Biol Chem 273 1998 17610 17617
7. S. Sarrió, V. Casadó, M. Escriche, F. Ciruela, J. Mallol, and E.I. Canela The heat shock cognate protein hsc73 assembles with A(1) adenosine receptors to form functional modules in the cell membrane Mol Cell Biol 20 2000 5164 5174
8. J. Burgueño, D.J. Blake, M.A. Benson, C.L. Tinsley, C.T. Esapa, and E.I. Canela The adenosine A(2A) receptor interacts with the actin-binding protein alpha-actinin J Biol Chem 278 2003 37545 37552
9. C. Saura, F. Ciruela, V. Casado, E.I. Canela, J. Mallol, and C. Lluis Adenosine deaminase interacts with A(1) adenosine receptors in pig brain cortical membranes J Neurochem 66 1996 1675 1682
10. O. Söderberg, M. Gullberg, M. Jarvius, K. Ridderstråle, K.J. Leuchowius, and J. Jarvius Direct observation of individual endogenous protein complexes in situ by proximity ligation Nat Methods 3 2006 995 1000
11. M. Gullberg, and A.C. Andersson Visualization and quantification of protein-protein interactions in cells and tissues Nat Methods 7 2010 5 6
12. S. Ferré, R. Baler, M. Bouvier, M.G. Caron, L.A. Devi, and T. Durroux Building a new conceptual framework for receptor heteromers Nat Chem Biol 5 2009 131 134
13. S. AbdAlla, H. Lother, A. el Massiery, and U. Quitterer Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness Nat Med 7 2001 1003 1009
14. M.L. González-Hernández, D. Godínez- Hernández, R.A. Bobadilla-Lugo, and P. López-Sánchez Angiotensin-II type 1 receptor (AT1R) and alpha-1D adrenoceptor form a heterodimer during pregnancy-induced hypertension Auton Autacoid Pharmacol 30 2010 167 172
15. R. Kaaja, T. Kinnunen, and R. Luoto Regional differences in the prevalence of pre-eclampsia in relation to the risk factors for coronary artery disease in women in Finland Eur Heart J 26 2005 44 50
16. C. Lydakis, M. Beevers, D.G. Beevers, and G.Y. Lip The prevalence of pre-eclampsia and obstetric outcome in pregnancies of normotensive and hypertensive women attending a hospital specialist clinic Int J Clin Pract 55 2001 361 367
17. R. Franco, V. Casadó, A. Cortés, J. Mallol, F. Ciruela, and S. Ferré G-protein-coupled receptor heteromers: function and ligand pharmacology Br J Pharmacol 153 Suppl. 1 2008 S90 S98 [Review]
18. P. Trifilieff, M.L. Rives, E. Urizar, R.A. Piskorowski, H.D. Vishwasrao, and J. Castrillon Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum Biotechniques 51 2011 111 118
19. S. González, D. Moreno-Delgado, E. Moreno, K. Pérez-Capote, R. Franco, and J. Mallol Circadian-related heteromerization of adrenergic and dopamine D4 receptors modulates melatonin synthesis and release in the pineal gland PLoS Biol 10 2012 e1001347
20. L. Callen, E. Moreno, P. Barroso-Chinea, D. Moreno-Delgado, A. Cortes, and J. Mallol Cannabinoid receptors CB1 and CB2 form functional heteromers in the brain J Biol Chem 287 2012 20851 20865
21. T. Kenakin Agonist-receptor efficacy. II. Agonist trafficking of receptor signals Trends Pharmacol Sci 16 1995 232 238
22. S. Granier, and B. Kobilka A new era of GPCR structural and chemical biology Nat Chem Biol 8 2012 670
23. R. Nygaard, Y. Zou, R.O. Dror, T.J. Mildorf, D.H. Arlow, and A. Manglik The dynamic process of β(2)-adrenergic receptor activation Cell 153 2013 532 542
24. G.M. West, E.Y.T. Chien, V. Katritch, J. Gatchalian, M.J. Chalmers, and R.C. Stevens Ligand-dependent perturbation of the conformational ensemble for the GPCR β2 adrenergic receptor revealed by HDX Structure 19 2011 1424 1432
25. A.W. Kahsai, K. Xiao, S. Rajagopal, S. Ahn, A.K. Shukla, and J. Sun Multiple ligand-specific conformations of the β2-adrenergic receptor Nat Chem Biol 7 2011 692 700
26. S. Ye, E. Zaitseva, G. Caltabiano, G.F.X. Schertler, T.P. Sakmar, and X. Deupi Tracking G-protein-coupled receptor activation using genetically encoded infrared probes Nature 464 2010 1386 1389
27. X.J. Yao, G.V. Ruiz, M.R. Whorton, S.G.F. Rasmussen, B.T. DeVree, and X. Deupi The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex Proc Natl Acad Sci USA 106 2009 9501 9506
28. X. Yao, C. Parnot, X. Deupi, V.R.P. Ratnala, G. Swaminath, and D. Farrens Coupling ligand structure to specific conformational switches in the β2-adrenoceptor Nat Chem Biol 2 2006 417 422
29. G. Swaminath, Y. Xiang, T.W. Lee, J. Steenhuis, C. Parnot, and B.K. Kobilka Sequential binding of agonists to the β2 adrenoceptor. Kinetic evidence for intermediate conformational states J Biol Chem 279 2004 686 691
30. A.C. MacKinnon, C. Waters, D. Jodrell, C. Haslett, and T. Sethi Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism J Biol Chem 276 2001 28083 28091
31. S. Mary, M. Damian, M. Louet, N. Floquet, J.-A. Fehrentz, and J. Marie Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor Proc Natl Acad Sci USA 109 2012 8304 8309
32. M. Zocher, J.J. Fung, B.K. Kobilka, and D.J. Müller Ligand-specific interactions modulate kinetic, energetic, and mechanical properties of the human β2 adrenergic receptor Structure 20 2012 1391 1402
33. P. Maurice, M. Kamal, and R. Jockers Asymmetry of GPCR oligomers supports their functional relevance Trends Pharmacol Sci 32 2011 514 520
34. L.M. Luttrell, and D. Gesty-Palmer Beyond desensitization: physiological relevance of arrestin-dependent signaling Pharmacol Rev 62 2010 305 330
35. J.A. Allen, J.M. Yost, V. Setola, X. Chen, M.F. Sassano, and M. Chen Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy Proc Natl Acad Sci 108 2011 18488 18493
36. E.J. Whalen, S. Rajagopal, and R.J. Lefkowitz Therapeutic potential of β-arrestin- and G protein-biased agonists Trends Mol Med 17 2011 126 139
37. F.M. Décaillot, M.A. Kazmi, Y. Lin, S. Ray-Saha, T.P. Sakmar, and P. Sachdev CXCR7/CXCR4 heterodimer constitutively recruits β-arrestin to enhance cell migration J Biol Chem 286 2011 32188 32197
38. D. Cervantes, C. Crosby, and Y. Xiang Arrestin orchestrates crosstalk between G protein-coupled receptors to modulate the spatiotemporal activation of ERK MAPK Circ Res 106 2009 1
39. A. Saulière, M. Bellot, H. Paris, C. Denis, F. Finana, and J.T. Hansen Deciphering biased-agonism complexity reveals a new active AT1 receptor entity Nat Chem Biol 8 2012 622 630
40. L. Prezeau, M.-L. Rives, L. Comps-Agrar, D. Maurel, J. Kniazeff, and J.-P. Pin Functional crosstalk between GPCRs: with or without oligomerization Curr Opin Pharmacol 10 2010 6 13
41. S. Rajagopal, J. Kim, S. Ahn, S. Craig, C.M. Lam, and N.P. Gerard β-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7 Proc Natl Acad Sci 107 2010 628 632
42. A. Levoye, K. Balabanian, F. Baleux, F. Bachelerie, and B. Lagane CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signalling Blood 113 2009 6085 6093
43. F.M. Decaillot, M.A. Kazmi, Y. Lin, S. Ray-Saha, T.P. Sakmar, and P. Sachdev CXCR7/CXCR4 heterodimer constitutively recruits {beta}-arrestin to enhance cell migration J Biol Chem 286 2011 32188 32197
44. G. Innamorati, F. Giannone, F. Guzzi, G.E. Rovati, M.R. Accomazzo, and B. Chini Heterotrimeric G proteins demonstrate differential sensitivity to beta-arrestin dependent desensitization Cell Signal 21 2009 1135 1142
45. M. Busnelli, A. Saulière, M. Manning, M. Bouvier, C. Galés, and B. Chini Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes J Biol Chem 287 2012 3617 3629
46. Y. Han, I.S. Moreira, E. Urizar, H. Weinstein, and J.A. Javitch Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation Nat Chem Biol 5 2009 688 695
47. J.S. Mason, A. Bortolato, M. Congreve, and F.H. Marshall New insights from structural biology into the druggability of G protein-coupled receptors Trends Pharmacol Sci 33 2012 249 260
48. G.E. de Kloe, D. Bailey, R. Leurs, and I.J.P. de Esch Transforming fragments into candidates: small becomes big in medicinal chemistry Drug Discov Today 14 2009 630 646
49. N.J. Smith, and G. Milligan Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes Pharmacol Rev 62 2010 701 725
50. M. De los Frailes, and E. Diez Screening technologies for G protein-coupled receptors: from HTS to uHTS Methods Mol Biol 552 2009 15 37
51. P. Leff The two-state model of receptor activation Trends Pharmacol Sci 16 1995 89 97
52. M. Canals, P.M. Sexton, and A. Christopoulos Allostery in GPCRs: "MWC" revisited Trends Biochem Sci 36 2011 663 672
53. K. Kristiansen Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function Pharmacol Ther 103 2004 21 80
54. B. Kobilka, and G.F.X. Schertler New G-protein-coupled receptor crystal structures: insights and limitations Trends Pharmacol Sci 29 2008 79 83
55. G.J. Digby, P.J. Conn, and C.W. Lindsley Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs Curr Opin Drug Discov Devel 13 2010 587 594
56. L.T. May, K. Leach, P.M. Sexton, and A. Christopoulos Allosteric modulation of G protein-coupled receptors Annu Rev Pharmacol Toxicol 47 2007 1 51
57. C.J. Langmead, and A. Christopoulos Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox Trends Pharmacol Sci 27 2006 475 481
58. V. Casadó, A. Cortés, J. Mallol, K. Pérez-Capote, S. Ferré, and C. Lluis GPCR homomers and heteromers: a better choice as targets for drug development than GPCR monomers? Pharmacol Ther 124 2009 248 257
59. V. Casadó, A. Cortés, F. Ciruela, J. Mallol, S. Ferré, and C. Lluis Old and new ways to calculate the affinity of agonists and antagonists interacting with G-protein-coupled monomeric and dimeric receptors: the receptor-dimer cooperativity index Pharmacol Ther 116 2007 343 354
60. R. Franco, V. Casadó, J. Mallol, C. Ferrada, S. Ferré, and K. Fuxe The two-state dimer receptor model: a general model for receptor dimers Mol Pharmacol 69 2006 1905 1912
61. R. Franco, V. Casadó, A. Cortés, K. Pérez-Capote, J. Mallol, and E. Canela Novel pharmacological targets based on receptor heteromers Brain Res Rev 58 2008 475 482
62. I. Gomes, A.P. Ijzerman, K. Ye, E.L. Maillet, and L.A. Devi G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding Mol Pharmacol 79 2011 1044 1052
63. J. González-Maeso, R.L. Ang, T. Yuen, P. Chan, N.V. Weisstaub, and J.F. López-Giménez Identification of a serotonin/glutamate receptor complex implicated in psychosis Nature 452 2008 93 97
64. C.W. Lindsley, and C.R. Hopkins Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature Expert Opin Ther Pat 22 2012 461 481
65. C.E. Müller, A.C. Schiedel, and Y. Baqi Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development Pharmacol Ther 135 2012 292 315
66. 1 receptor antagonists for the treatment of Parkinson's disease J Med Chem 55 2012 1402 1417
67. M. Vendrell, E. Angulo, V. Casadó, C. Lluis, R. Franco, and F. Albericio Novel ergopeptides as dual ligands for adenosine and dopamine receptors J Med Chem 50 2007 3062 3069
68. F. Ciruela, V. Casadó, R.J. Rodrigues, R. Luján, J. Burgueño, and M. Canals Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers J Neurosci 26 2006 2080 2087
69. A.J. Rashid, C.H. So, M.M. Kong, T. Furtak, M. El-Ghundi, and R. Cheng D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum Proc Natl Acad Sci USA 104 2007 654 659
70. P.S. Portoghese From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes J Med Chem 44 2001 2259 2269
71. C. Valant, L.J. Robert, P.M. Sexton, and A. Christopoulos The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors Annu Rev Pharmacol Toxicol 52 2012 153 178
72. A. Soriano, R. Ventura, A. Molero, R. Hoen, V. Casadó, and A. Cortés Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers J Med Chem 52 2009 5590 5602
73. J. Kühhorn, H. Hübner, and P. Gmeiner Bivalent dopamine D2 receptor ligands: synthesis and binding properties J Med Chem 54 2011 4896 4903
74. O. Russo, M. Berthouze, M. Giner, J.L. Soulier, L. Rivail, and S. Sicsic Synthesis of specific bivalent probes that functionally interact with 5-HT(4) receptor dimers J Med Chem 50 2007 4482 4492
75. S. Halazy, M. Perez, C. Fourrier, I. Pallard, P.J. Pauwels, and C. Palmier Serotonin dimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT(1B/1D) agonists J Med Chem 39 1996 4920 4927
76. H.L. Handl, R. Sankaranarayanan, J.S. Josan, J. Vagner, E.A. Mash, and R.J. Gillies Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R) Bioconjug Chem 18 2007 1101 1109
77. Y. Yuan, C.K. Arnatt, G. Li, K.M. Haney, D. Ding, and J.C. Jacob Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5 Org Biomol Chem 10 2012 2633 2646
78. M. Thelen, L.M. Muñoz, J.M. Rodríguez-Frade, and M. Mellado Chemokine receptor oligomerization: functional considerations Curr Opin Pharmacol 10 2009 38 43
79. L.M. Muñoz, P. Lucas, B.L. Holgado, R. Barroso, B. Vega, and J.M. Rodríguez-Frade Receptor oligomerization: a pivotal mechanism for regulating chemokine function Pharmacol Ther 131 2011 351 358
80. J.Y. Springael, E. Urizar, and M. Parmentier Dimerization of chemokine receptors and its functional consequences Cytokine Growth Factor Rev 16 2005 611 623
81. T. Tanaka, W. Nomura, T. Narumi, A. Masuda, and H. Tamamura Bivalent ligands of CXCR4 with rigid linkers for elucidation of the dimerization state in cells J Am Chem Soc 132 2010 15899 15901
82. M.D. Metcalf, A.S. Yekkirala, M.D. Powers, K.F. Kitto, C.A. Fairbanks, and G.L. Wilcox The δ opioid receptor agonist SNC80 selectively activates heteromeric μ-δ opioid receptors ACS Chem Neurosci 3 2012 505 509
83. A. Hasbi, T. Fan, M. Alijaniaram, T. Nguyen, M.L. Perreault, and B.F. O'Dowd Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth Proc Natl Acad Sci USA 106 2009 21377 21382
84. M. Orru, J. Bakesová, M. Brugarolas, C. Quiroz, V. Beaumont, and S.R. Goldberg Striatal pre- and postsynaptic profile of adenosine A2A receptor antagonists PLoS One 6 2011 e16088
85. R. Franco, V. Casadó, J. Mallol, S. Ferré, K. Fuxe, and A. Cortés Dimer-based model for heptaspanning membrane receptors Trends Biochem Sci 30 2005 360 366
86. L.A. Hu, T. Zhou, B.D. Hamman, and Q. Liu A homogeneous G protein-coupled receptor ligand binding assay based on time-resolved fluorescence resonance energy transfer Assay Drug Dev Technol 6 2008 543 550
87. M. Kocan, M.B. Dalrymple, R.M. Seeber, B.J. Feldman, and K.D. Pfleger Enhanced BRET technology for the monitoring of agonist-induced and agonist-independent interactions between GPCRs and β-arrestins Front Endocrinol 1 2010 12
88. H.B. See, R.M. Seeber, M. Kocan, K.A. Eidne, and K.D. Pfleger Application of G protein-coupled receptor-heteromer identification technology to monitor β-arrestin recruitment to G protein-coupled receptor heteromers Assay Drug Dev Technol 9 2011 21 30